Literature DB >> 33850315

Circulating spexins in children with obesity: relation to cardiometabolic risk.

Nouran Y Salah1, Dina Abu Zeid2, Rania N Sabry2, Reham F Fahmy2, Mona A El Abd2, Eman Awadallah3, Azza Omran4, Yasmin G El Gendy5.   

Abstract

BACKGROUND/
OBJECTIVES: The role of spexin (SPX) in energy metabolism, endocrinal homeostasis, and vasculopathy is emerging. However, scarce data are available about its role in childhood obesity and obesity-related vasculopathy. Hence, we aimed to assess the level of SPX in obese and normal-weight children, and to correlate it with aortic distensibility (AD) and aortic stiffness index (ASI). SUBJECTS/
METHODS: Forty obese children were compared to 40 matched normal-weighed children. Weight, height, and body mass index (BMI) z score and mean blood pressure (Bl-Pr) percentile on three different occasions were obtained. SPX, fasting triglycerides, cholesterol, low-density (LDL), high-density lipoproteins (HDL), and insulin were measured with calculation of the homeostatic model assessment insulin resistance (HOMA-IR). Internal aortic diameter was measured with calculation of AD, strain (AS), and ASI.
RESULTS: Children with obesity had significantly lower SPX (P = 0.004), HDL (P < 0.001), and AD (P < 0.001) and higher systolic Bl-Pr (P < 0.001), diastolic Bl-Pr (P < 0.001), LDL (P = 0.011), HOMA-IR (P < 0.001), and ASI (P < 0.001). Significant negative correlation was found between SPX and BMI z score (r = -0.646, P < 0.001), systolic Bl-Pr (r = -0.641, P < 0.001), diastolic Bl-Pr (r = -0.427, P < 0.001), HOMA-IR (r = -0.349, P = 0.028), and ASI (r = -0.389, P = 0.013), while significant positive correlation was found between SPX and AS (P < 0.001, r = 0.633) and AD (P < 0.001, r = 0.612). However, no significant correlation was found between SPX and age (r = -0.01, P = 0.953), TG (r = 0.048, P = 0.767), total cholesterol (r = -0.023, P = 0.887), LDL (r = -0.299, P = 0.061), and HDL (r = 0.193, P = 0.232).
CONCLUSIONS: Children with obesity had significantly lower SPX than controls. SPX was correlated with BMI, Bl-Pr, HOMA-IR, and vasculopathy in children with obesity independent of their age and lipid profile. Further studies should explore the pathomechanism of SPX and its potential role in the management of obesity and obesity-related cardiometabolic risk.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33850315     DOI: 10.1038/s41430-021-00912-7

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  12 in total

1.  Different spexin level in obese vs normal weight children and its relationship with obesity related risk factors.

Authors:  Maryam Behrooz; Elnaz Vaghef-Mehrabany; Alireza Ostadrahimi
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-11-23       Impact factor: 4.222

2.  Effect of obesity and type 2 diabetes, and glucose ingestion on circulating spexin concentration in adolescents.

Authors:  S Konnar Hodges; April M Teague; Paul S Dasari; Kevin R Short
Journal:  Pediatr Diabetes       Date:  2017-06-19       Impact factor: 4.866

3.  Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.

Authors:  Joseph T Flynn; David C Kaelber; Carissa M Baker-Smith; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Susan K Flinn; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina
Journal:  Pediatrics       Date:  2017-08-21       Impact factor: 7.124

Review 4.  Spexin as a neuroendocrine signal with emerging functions.

Authors:  Ani Ma; Jin Bai; Mulan He; Anderson O L Wong
Journal:  Gen Comp Endocrinol       Date:  2018-01-31       Impact factor: 2.822

5.  Circulating spexin levels are influenced by the presence or absence of gestational diabetes.

Authors:  Nasser M Al-Daghri; Shaun Sabico; Hazim Al-Hazmi; Amal M Alenad; Abeer Al-Amro; Amani Al-Ghamdi; Syed Danish Hussain; George Chrousos; Majed S Alokail
Journal:  Cytokine       Date:  2018-07-19       Impact factor: 3.861

6.  Childhood risk factors and carotid atherosclerotic plaque in adulthood: The Cardiovascular Risk in Young Finns Study.

Authors:  Juhani S Koskinen; Ville Kytö; Markus Juonala; Jorma S A Viikari; Jaakko Nevalainen; Mika Kähönen; Terho Lehtimäki; Nina Hutri-Kähönen; Tomi Laitinen; Päivi Tossavainen; Eero Jokinen; Costan G Magnussen; Olli T Raitakari
Journal:  Atherosclerosis       Date:  2019-11-30       Impact factor: 5.162

7.  Spexin Enhances Bowel Movement through Activating L-type Voltage-dependent Calcium Channel via Galanin Receptor 2 in Mice.

Authors:  Cheng-yuan Lin; Man Zhang; Tao Huang; Li-ling Yang; Hai-bo Fu; Ling Zhao; Linda L D Zhong; Huai-xue Mu; Xiao-ke Shi; Christina F P Leung; Bao-min Fan; Miao Jiang; Ai-ping Lu; Li-xin Zhu; Zhao-xiang Bian
Journal:  Sci Rep       Date:  2015-07-10       Impact factor: 4.379

8.  Development of Spexin-based Human Galanin Receptor Type II-Specific Agonists with Increased Stability in Serum and Anxiolytic Effect in Mice.

Authors:  Arfaxad Reyes-Alcaraz; Yoo-Na Lee; Gi Hoon Son; Nam Hoon Kim; Dong-Kyu Kim; Seongsik Yun; Dong-Hoon Kim; Jong-Ik Hwang; Jae Young Seong
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

Review 9.  Emerging Roles of NPQ/Spexin in Physiology and Pathology.

Authors:  Shuang-Yu Lv; Yu-Chen Zhou; Xiao-Mei Zhang; Wei-Dong Chen; Yan-Dong Wang
Journal:  Front Pharmacol       Date:  2019-05-07       Impact factor: 5.810

Review 10.  Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.

Authors:  Un Ju Jung; Myung-Sook Choi
Journal:  Int J Mol Sci       Date:  2014-04-11       Impact factor: 5.923

View more
  1 in total

Review 1.  Impact of spexin on metabolic diseases and inflammation: An updated minireview.

Authors:  İbrahim Türkel; Gülsün Memi; Burak Yazgan
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.